Nature Search

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Breast cancer risk for BRCA1/BRCA2 mutation carriers varies depending on other genetic factors. Here, the authors perform a case-only genome-wide association study and highlight novel loci associated with breast cancer risk for BRCA1/BRCA2 mutation carriers.

Juliette Coignard
Michael Lush
Antonis C. Antoniou
ResearchOpen Access17 Feb 2021
Nature Communications

Volume: 12, P: 1-22
Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ

Louisa Lisa Lo
Roger Laughlin Milne
Kelly-Anne Phillips
ResearchOpen Access21 Jun 2018
British Journal of Cancer

Volume: 119, P: 36-39
Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Kelly-Anne Phillips
Meredith M Regan
Jürg Bernhard
ResearchOpen Access19 Apr 2016
British Journal of Cancer

Volume: 114, P: 956-964
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Daniel R. Barnes
Matti A. Rookus
Antonis C. Antoniou
ResearchOpen Access15 Jul 2020
Genetics in Medicine

Volume: 22, P: 1653-1666
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Paul Pharoah and colleagues report the results of a large genome-wide association study of ovarian cancer. They identify new susceptibility loci for different epithelial ovarian cancer histotypes and use integrated analyses of genes and regulatory features at each locus to predict candidate susceptibility genes, including OBFC1.

Catherine M Phelan
Karoline B Kuchenbaecker
Paul D P Pharoah
Research27 Mar 2017
Nature Genetics

Volume: 49, P: 680-691
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Alison Dunning, Stacey Edwards and colleagues analyze 3,872 common variants across the ESR1 locus in 118,816 women. They find five independent variants within regulatory regions that associate with different breast cancer–related phenotypes and regulate the expression of ESR1, RMND1 and CCDC170.

Alison M Dunning
Kyriaki Michailidou
Stacey L Edwards
Research29 Feb 2016
Nature Genetics

Volume: 48, P: 374-386
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice

In preclinical studies, Hutt, Loi and colleagues find that mice treated with checkpoint blockade have impaired ovarian function and reserve, associated with increased immune infiltrate, raising considerations about fertility implications for female patients.

Amy L. Winship
Lauren R. Alesi
Karla J. Hutt
Research25 Aug 2022
Nature Cancer

Volume: 3, P: 1-13
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

Studies have shown that breast cancer prognosis is hereditary. Here the authors show that a genetic variant in CCL20, a chemokine ligand involved in immune response, is significantly associated with breast cancer survival and may therefore represent an important therapeutic or prognostic target.

Jingmei Li
Linda S. Lindström
Kamila Czene
ResearchOpen Access17 Jun 2014
Nature Communications

Volume: 5, P: 1-9
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Genome-wide analysis identifies 32 loci associated with breast cancer susceptibility, accounting for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status and tumor grade.

Haoyu Zhang
Thomas U. Ahearn
Montserrat García-Closas
Research18 May 2020
Nature Genetics

Volume: 52, P: 572-581
Association analysis identifies 65 new breast cancer risk loci

Association analysis identifies 65 new breast cancer risk loci, predicts target genes for known risk loci and demonstrates a strong overlap with somatic driver genes in breast tumours.

Kyriaki Michailidou
Sara Lindström
Douglas F. Easton
Research23 Oct 2017
Nature

Volume: 551, P: 92-94
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab

Hongyan Li
Bingjian Feng
David E. Goldgar
Research12 May 2016
Genetics in Medicine

Volume: 19, P: 30-35
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Juliette Coignard
Michael Lush
Antonis C. Antoniou
Amendments and CorrectionsOpen Access14 May 2021
Nature Communications

Volume: 12, P: 1-2
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

Taru A. Muranen
Anna Morra
Heli Nevanlinna
ResearchOpen Access12 May 2023
npj Breast Cancer

Volume: 9, P: 1-15
Key steps for effective breast cancer prevention

This Review presents the evidence for the role of risk factors in breast cancer incidence and their inclusion in risk estimation tools as a step towards precision prevention to specifically target those women at increased risk for appropriate risk-reducing interventions.

Kara L. Britt
Jack Cuzick
Kelly-Anne Phillips
Reviews11 Jun 2020
Nature Reviews Cancer

Volume: 20, P: 417-436
Survival from breast cancer in women with a BRCA2 mutation by treatment

D. Gareth Evans
Kelly-Anne Phillips
Marie Wood
Research18 Feb 2021
British Journal of Cancer

Volume: 124, P: 1524-1532
Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment

D. Gareth Evans
Kelly-Anne Phillips
Marie Wood
Amendments and Corrections13 Jan 2023
British Journal of Cancer

Volume: 128, P: 703
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Inge M. M. Lakeman
Alexandra J. van den Broek
Marjanka K. Schmidt
ResearchOpen Access10 Jun 2021
Genetics in Medicine

Volume: 23, P: 1726-1737

Search

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Association analysis identifies 65 new breast cancer risk loci

Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab

Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

Key steps for effective breast cancer prevention

Survival from breast cancer in women with a BRCA2 mutation by treatment

Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Search

Quick links

Search

Filter By:

Search

Quick links